Lilly, Novartis, and Sanofi sent HRSA defiant responses to its May 17 letters telling the companies that their 340B contract pharmacy policies were illegal.
On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it [...] …
A federal court sided with a group of Texas hospitals’ efforts to block an HHS rule.
Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing [...] …
Massachusetts Medicaid director Daniel Tsai has been named Director of CMS’s Center for Medicaid and CHIP Services.
The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been [...] …
HRSA recently held a webinar for hospitals ahead of their annual 340B recertification period.
Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health [...] …
A recent Supreme Court decision was a big win for 340B providers, K&L Gates partners (left to right) Don Walker, Leah D’Aurora Richardson, and Victoria Hamscho say in a new American Health Law Association paper.
A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing [...] …
In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four questions that need to be addressed in the contract pharmacy standoff.
In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four burning questions as we approach [...] …
Safety net facilities are celebrating the May 17 HRSA letters to six drug manufacturers affirming they must provide drugs to [...] …
HHS Secretary Xavier Becerra made appointments today to the 340B administrative dispute resolution board. | Shutterstock
U.S. Health and Human Services (HHS) Secretary Xavier Becerra early this morning announced his six appointees to the long-awaited 340B [...] …
Covered entities' monthly 340B savings on Sanofi products dropped from $54.2 million just before the company limited discounts on drugs shipped to contract pharmacies to about $5 million within two months, federal lawyers told a judge last week.
Hospitals, health centers, and clinics are losing a projected $3.2 billion a year in 340B program savings due to six [...] …
AbbVie and AstraZeneca filed a pair of lawsuits to block Minnesota's law barring manufacturer 340B contract pharmacy restrictions.
Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling [...] …
*Sign up for news summaries and alerts from 340B Report
Copyright © 2025 340B Report, LLC
Reproduction of material from any 340B Report page without written permission is strictly prohibited.
